InvestorsHub Logo
Followers 12
Posts 1052
Boards Moderated 1
Alias Born 08/28/2020

Re: None

Thursday, 12/28/2023 11:22:10 PM

Thursday, December 28, 2023 11:22:10 PM

Post# of 22619
Per Chris's analysis of Biotech growth 2024... companies with compelling clinical data and closest to market with a first in class therapeutic drug will be the prime candidates for funding or IPO. Vyome with VB-1953 fits that description perfectly. (A Reverse Merger would be the same as an IPO as it is a more expedient and cost-efficient method to go public).
Bullish
Bullish